Sanofi nabs speedy review of sutimlimab, aiming for a November approval

After posting positive late-stage results for its rare blood disease drug, Sanofi has been handed a priority review from the FDA for sutimlimab.

The French Big Pharma is hoping that its complement C1s inhibitor will get a green light for use in cold agglutinin disease (CAD), a rare condition in which the immune system turns on the patient’s red blood cells.